MIP-11

250 views
174 views

Published on

26-28 MAY, 2013 - FIRST ANNUAL YOUTH ENTREPRENEURSHIP AND INNOVATORS CONFERENCE IN RUSSIA. STARTUP VILLAGE - one of the most ambitious start-up conferences in Russia, organized by Skolkovo in cooperation with partners. The conference is the first this year and will be held annually.

MIP-11 is the first conference day's pitch session participant in the Life Science pavillion.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
250
On SlideShare
0
From Embeds
0
Number of Embeds
7
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

MIP-11

  1. 1. Development of innovative drug fortreatment of Hepatitis CMIP-11Mefodieva Lyudmilamlg@pharmcluster.ru8-964-709-98-57
  2. 2. Hepatitis C170 millionpeople infected with HCV$ 4 billionGlobal HCV market$ 0,3 billionRussia HCV marketMarket5 millionpeople infected with HCVin RussiaPrevalenceHCV350 000people die each year fromHCV complicationsLiver with CirrhosisNormal LiverLead to chronic hepatitis,liver cirrhosis,hepatocellular carcinoma
  3. 3. AVR-560 HCV entry inhibitor
  4. 4. Before AVR-560 After AVR-560AVR-560 promising drug candidate
  5. 5. AVR-560 road map$$$ Grants and investments2007-2010PreclinicaldevelopmentProof-of-concept(phase I, II) Phase IIIDiscovery2011-20122013-20142015-2016AVR-560
  6. 6. Intellectual propertyRussian patent National phasePCT publicationRU 2436786, 20.12.2011 WO 2012/011847 A1, 26.01.12Priority date 23.07.2010
  7. 7. Team & PartnersCEOKorzinov OlegCSOVadim Bichkosuccessful drug development from earlydiscovery stage to the clinic, includingvalopicitabine) into Phase 2GR, PR, fund raising, VCcommunication, creation of academicand universities partnershipsCCONatalia VostokovaClinical Trials Experience> 15 Audits4 FDA inspections in 2009Preclinical& FormulationAnalyticalstudiesClinical trialslaboratories equipped inaccordance with theinternational GLP standardand fitted with high techfacilitiesCRO, clinical trialsmanagement- Clinical center,17 diverse clinics for3000 patientscenter executing contractR&D in the field of pre-clinical and clinicalresearches of innovativedrugs
  8. 8. Business modelMIP-11Russia+CISWorldOut-licensing to Russian Pharm companyOut-licensing to Big Pharma
  9. 9. ExamplesCase 1 Case 2Gilead Sciences to AcquirePharmasset, Inc. for $11 Billion:PSI-7977 – phase 3;PSI-938 – phase 2b;RG7128 – phase 2bBristol-Myers Squibb to AcquireInhibitex, Inc. for $2,5 Billion:INX-189 - phase 2
  10. 10. Thank you!Mefodieva Lyudmilamlg@pharmcluster.ru8-964-709-98-57

×